Guard Therapeutics International AB

GUARD

SE0021181559

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 10/09/2024 BST			5-day change	1st Jan Change
29.00 ^SEK	+2.11%		+0.69%	-18.99%

08-29	First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	CI
08-27	Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Guard Therapeutics International AB

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	08-29	CI
Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	08-27	MT
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-22	CI
Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter	08-08	CI
Guard Therapeutics Announces Scientific Journal American Journal of Physiology ? Renal Physiology Publishes Article Summarizing Important Preclinical Results of Its Clinical Drug Candidate RMC-035	05-27	CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Guard Therapeutics International AB announced that it expects to receive SEK 59.99074 million in funding from Swedbank Robur Fonder AB, Industrifonden, Strand Kapitalforvaltning AB and another investor	05-07	CI
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	04-15	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	01-31	CI
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges	01-15	MT
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	01-15	CI
Guard Therapeutics International AB Appoints Nomination Committee for 2024	12-07	CI
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035	28/09/23	CI
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program	19/09/23	CI
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA	14/07/23	CI
Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation	14/06/23	CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Guard Therapeutics Provides Updated Information on the Phase 2 Study AKITA	02/05/23	CI
Guard Therapeutics Plummets 87% Amid Termination of Mid-stage Trial for Kidney Failure Drug	14/04/23	MT
Guard Therapeutics International AB Presents Positive Clinical Data with RMC-035 in Patients Undergoing Kidney Transplantation	16/03/23	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	22/02/23	CI

Chart Guard Therapeutics International AB

Duration

Period

Chart Guard Therapeutics International AB

More charts

A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11/2024 - Q3 2024 Earnings Release

More about the company